Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Aug 5:105:adv44198.
doi: 10.2340/actadv.v105.44198.

Impact of Vitiligo on Major Life-changing Decisions and Perceived Stigmatization: A Cross-sectional Study

Lucía Castellano-Lopezosa  1 , Clara Ureña Paniego  2 , Sofía Haselgruber  2 , Gonzalo Blasco-Morente  2 , Salvador Arias-Santiago  3
Affiliations
Observational Study

Impact of Vitiligo on Major Life-changing Decisions and Perceived Stigmatization: A Cross-sectional Study

Lucía Castellano-Lopezosa et al. Acta Derm Venereol. .

Abstract

Vitiligo is a chronic autoimmune disease that profoundly affects patients' quality of life. A cross--sectional, observational study was conducted with 51 patients using self-administered questionnaires, with the aim to evaluate the impact of vitiligo on major life-changing decisions (MLCDs) as well as on stigmatization using a modified version of the Patient Unique Stigmatization Holistic tool in dermatology (PUSH-D) scale. Results showed that the most affected MLCDs were clothing choices, social interactions, and lifestyle changes. Facial vitiligo was significantly associated with a greater impact on work-related decisions. Factors such as being single, not having children, being female, and longer disease duration were linked to higher impact on life decisions. The study emphasizes the importance of addressing both clinical severity and the psychological burden of vitiligo to improve patient care.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Box-plot diagrams representing the severity of vitiligo based on SAVASI scores (left) and facial involvement (right). SAVASI: Severity of Alopecia and Vitiligo Activity and Severity Index.
Fig. 2
Fig. 2
Perceived severity of the disease.
Fig. 3
Fig. 3
Percentage of patients showing a moderate to high impact of vitiligo on MLCD. Only the most affected MLCDs are shown. MLCD: major life-changing decisions.
Fig. 4
Fig. 4
Results of the modified version of the Patient Unique Stigmatization Holistic tool in dermatology.
See this image and copyright information in PMC

References

    1. Pérez-Bootello J, Cova-Martín R, Naharro-Rodríguez J, Segurado-Miravalles G. Vitiligo: pathogenesis and new and emerging treatments. Int J Mol Sci 2023; 24: 17306. 10.3390/ijms242417306 - DOI - PMC - PubMed
    1. Kang C. Ruxolitinib cream 1.5%: a review in non-segmental vitiligo. Drugs 2024; 84: 579–586. 10.1007/s40265-024-02027-2 - DOI - PMC - PubMed
    1. Eleftheriadou V, Ahmed A, Nesnas J, Nagra R. The lifetime risk and impact of vitiligo across sociodemographic groups: a UK population-based cohort study. Br J Dermatol 2024; 192: 63–71. 10.1093/bjd/ljae282 - DOI - PubMed
    1. Rosmarin D, Soliman AM, Piercy J, Marwaha S, Anderson P, Camp HS. Health-related quality-of-life burden among adults with vitiligo: relationship to disease severity and disease location. Dermatol Ther (Heidelb) 2024; 14: 1633–1647. 10.1007/s13555-024-01187-z - DOI - PMC - PubMed
    1. Seneschal J. Clinical features of vitiligo and social impact on quality of life. Dermatol Pract Concept 2023; 13: e2023312S. 10.5826/dpc.1304S2a312S - DOI - PMC - PubMed

Publication types

LinkOut - more resources